Synchrotron

Letter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies

Retrieved on: 
Tuesday, October 17, 2023
Technology, Medical Devices, Hospitals, FDA, Health Technology, Software, Biotechnology, Radiology, Health, Oncology, TBG, BMI, Cyclotron, Family, Synchrotron, Seed, Gold, Radiation, Radiation therapy, Research

TeamBest Global (TBG) is a lean enterprise consisting of multiple companies, some of which were failing when Krishnan Suthanthiran acquired them.

Key Points: 
  • TeamBest Global (TBG) is a lean enterprise consisting of multiple companies, some of which were failing when Krishnan Suthanthiran acquired them.
  • TBG companies have grown to support 450+ employees globally and work to revitalize struggling companies with new product lines.
  • Suthanthiran considers his staff his family, striving daily to ensure that employees—along with suppliers and contractors—are paid and customers are happy and satisfied.
  • His companies offer a wide range of cyclotrons and synchrotrons for radioisotope production, research, and therapy.

Improved Pharma presenting at AAPS 2022 PHARMASCI 360 with Rapid Fire Presentation and Posters

Retrieved on: 
Tuesday, September 27, 2022
Micro-g environment, Synchrotron, SXRD, SSCI, Tablet, Payload, XRD, Lenticular Reentry Vehicle, Crystallization, COO, Ritonavir, Raman, WEST, III, Rapid Fire, AAPS, California Green Chemistry Initiative, Consultant, AB, Research, Complex, Pharmaceutical industry, Fine chemical

WEST LAFAYETTE, Ind., Sept. 27, 2022 /PRNewswire-PRWeb/ -- Improved Pharma is presenting their research on all three days of the AAPS conference. On Monday October 17th at 2:30 pm, please visit monitor #31 in forum 6. Ms. Ruba Alajlouni will present "Feasibility of Synchrotron XRD for the analysis of mixture sub-samples." She will share results demonstrating the effective utilization of synchrotron XRD (SXRD) for the analysis of mixtures.

Key Points: 
  • WEST LAFAYETTE, Ind., Sept. 27, 2022 /PRNewswire-PRWeb/ -- Improved Pharma is presenting their research on all three days of the AAPS conference .
  • On Tuesday, Improved Pharma has two posters presented concurrently at 2:30 pm in forum 8 (monitor numbers 45 and 46).
  • Dr. Susan-Bogdanowich-Knipp, President of Ravine Pharmaceuticals and Consultant with Improved Pharma, will present "Green Chemistry Initiative for Formulating, Pressing and Evaluating Tablets in Low-Resource Settings."
  • Improved Pharma is also designing and testing hardware that will provide antisolvent crystallization and evaporation capabilities in microgravity.

Prof. Zelig Tochner Tells How To Install Proton Therapy in Existing Radiation Linac Vaults

Retrieved on: 
Tuesday, August 30, 2022
Proton, University, 3D, Cancer, Synchrotron, Arm, Trial of the century, Solution, CT, Proton therapy, Hebrew language, Steven Naifeh, Orientation, Radiation therapy, Hadassah Medical Center, National University of Singapore, MD, Philadelphia, Hospital, TEL, FDA, Neutron, Oncology, ROI, PBS, TPS, CE, National university, Acquisition, Einstein Medical Center Philadelphia, Patient, Medical imaging, Radiation

TEL AVIV, Israel, Aug. 30, 2022 /PRNewswire-PRWeb/ -- Despite the proven and potential clinical benefits of proton therapy, this treatment is currently available to very few patients. The reasons are primarily economic. Until now, the equipment size required its own dedicated building. Combining construction and heavy equipment cost severely limited the potential for cost-effective operation and ROI in a reasonable period. Previously, the dimension of proton therapy equipment – accelerator, beam delivery, treatment planning and delivery room -- did not allow for integration of the equipment within existing radiotherapy practice facilities. Because of the constraints of legacy equipment and design, combined with the substantial cost to develop, build and operate a stand-alone proton center, the expansion of proton treatment to existing radiotherapy centers, and to physician-owned centers, has been extremely limited.

Key Points: 
  • Despite all of the above, due to the clinical benefits demonstrated since 1954, proton therapy has become a significant tool to fight cancer with radiation.
  • Proton therapy can now be centered in an existing linac vault.
  • To do so, there are five requirements to allow healthcare provider to integrate proton therapy into an operating radiotherapy department, while eliminating the barriers of installing and operating existing legacy proton therapy systems.
  • A Professor Emeritus and the former medical director of the Roberts Proton Therapy Center at the University of Pennsylvania Medical Center, one of the world's largest proton therapy facilities.

Particle Therapy Market - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 19, 2022
Health, Other Health, Proton, Research, Cancer, Hospital, CAGR, Proton therapy, LLC, Particle, Synchrotron, Cyclotron, USD, Radiation, Government, Hitachi, Medical imaging, Healthcare, EU

The particle therapy market is projected to reach USD 1,004 million by 2027 from USD 677 million in 2022, growing at a CAGR of 8.2% from 2022 to 2027.

Key Points: 
  • The particle therapy market is projected to reach USD 1,004 million by 2027 from USD 677 million in 2022, growing at a CAGR of 8.2% from 2022 to 2027.
  • Market growth is driven by factors such as the various advantages offered by the growing global prevalence of cancer, particle therapy advantages over photon therapy, increasing acceptance of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide.
  • In 2021, the treatment applications segment is projected to account for the dominant share of 94.4% of the particle therapy market.
  • On the basis of type, the particle therapy market is segmented into proton therapy and heavy ion therapy.

Global Radiation Therapy in the Oncology Market (2021 to 2031) - Featuring Accuray, Elekta and General Electric Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, August 9, 2021
Radiology, Health, Oncology, Zap, CAGR, Diagnosis, Siemens, ICAD Inc., Hitachi, Cancer, Synchrocyclotron, HDR, Radiation, Industry, Proton, Growth, Patient, Varian Medical Systems, Synchrotron, Oncology, Safety, Photon, LINAC, General Electric Company, Cyclotron, Medical imaging, Pharmaceutical industry

Radiation therapy in the oncology market is a treatment method to treat any type of cancer/tumor with the help of radiation.

Key Points: 
  • Radiation therapy in the oncology market is a treatment method to treat any type of cancer/tumor with the help of radiation.
  • The term 'radiation therapy' mostly refers to external beam radiation therapy, but it also means internal beam radiation therapy too.
  • What are the major market drivers, challenges, and opportunities in the global radiation therapy in oncology market?
  • What was the market value of the leading segments of the global radiation therapy in oncology market in 2020?

Inprentus Confirms New Contracts for the Sale of Diffraction Gratings for X-ray Optics Applications at Synchrotron Light Sources in US and Brazil

Retrieved on: 
Tuesday, November 10, 2020
Electromagnetic radiation, Physics, Physical sciences, Accelerator physics, Synchrotron radiation, Light sources, Diffraction grating, Photonics, Laboratório Nacional de Luz Síncrotron, Synchrotron light source, Synchrotron, Beamline

CHAMPAIGN, Ill., Nov. 10, 2020 /PRNewswire-PRWeb/ --Inprentus serves the x-ray optics scientific community globally, providing blazed diffraction gratings for synchrotron and free electron laser light sources around the world.

Key Points: 
  • CHAMPAIGN, Ill., Nov. 10, 2020 /PRNewswire-PRWeb/ --Inprentus serves the x-ray optics scientific community globally, providing blazed diffraction gratings for synchrotron and free electron laser light sources around the world.
  • Inprentus has been awarded a contract to provide Lawrence Berkeley National Lab's Advanced Light Source (ALS) with a diffraction grating for its MERLIN beamline.
  • The Brazilian Synchrotron Light Laboratory (LNLS) is responsible for the operation of the only synchrotron light source in Latin America.
  • Inprentus was founded in June 2012 to commercialize an innovative, nano-scale lithography technology using mechanical deformation of metallic surfaces.

Ryvu Therapeutics Has Completed the Construction of the R&D Center for Innovative Drugs

Retrieved on: 
Tuesday, June 2, 2020
Operating systems, Computer architecture, Proprietary software, Jagiellonian University, Solaris, Synchrotron radiation, Synchrotron

Construction of own R&D Centre constitutes an element of execution of the strategic plans focused on the discovery and development of innovative therapies announced in 2017.

Key Points: 
  • Construction of own R&D Centre constitutes an element of execution of the strategic plans focused on the discovery and development of innovative therapies announced in 2017.
  • The R&D Center for Innovative Drugs is situated in close proximity to the Jagiellonian University as well as Solaris Synchrotron Facility.
  • The initiative to honor Dr. Sternbach, was spearheaded by Ryvu and received strong support from Krakow scientific and technology community.
  • Its launch will allow Ryvu to expand the pipeline and accelerate research process of innovative drugs.

Alfa Laval Conducted Ground-breaking Material Research at MAX IV Synchrotron Radiation Facility in Sweden

Retrieved on: 
Wednesday, April 22, 2020
Economy of Sweden, Accelerator physics, Alfa Laval, MAX IV Laboratory, Counties of Sweden, Synchrotron, Lund, Municipalities of Sweden

During March, Alfa Laval conducted a four days state-of-the-art experiment at the MAX IV synchrotron radiation facility in Lund, Sweden.

Key Points: 
  • During March, Alfa Laval conducted a four days state-of-the-art experiment at the MAX IV synchrotron radiation facility in Lund, Sweden.
  • "The experiment was very successful and gave us valuable insights about the oxide and how it reacts to high temperatures," says Tom Erixon, President and CEO of Alfa Laval.
  • The Swedish-based laboratory MAX IV is the most modern synchrotron radiation facility in the world, and it is using the most brilliant X-ray light ever generated.
  • Thereby, Alfa Laval is not only accelerating success for its customers, but also for people and the planet.

Best Medical International Signs a Memorandum of Understanding with University of Wisconsin Medical Radiation Research Center (UWMRRC) to Develop Revolutionary New Carbon Therapy

Retrieved on: 
Thursday, January 30, 2020
University, Biotechnology, Education, Managed care, Health, Radiology, Oncology, Medical devices, Research, Hospitals, Science, Physical sciences, Physics, Natural sciences, Medical physics, Radiobiology, Accelerator physics, Radioactivity, Particle therapy, Synchrotron, Radiation therapy, Hera, Ionizing radiation

Best Medical International and Best Particle Therapy of TeamBest Companies, have recently entered into a Memorandum of Understanding (MOU) with the University of Wisconsin Medical Radiation Research Center (UWMRRC).

Key Points: 
  • Best Medical International and Best Particle Therapy of TeamBest Companies, have recently entered into a Memorandum of Understanding (MOU) with the University of Wisconsin Medical Radiation Research Center (UWMRRC).
  • Best Particle Therapy will be introducing their unique 400 MeV ion Rapid Cycling Medical Synchrotron (iRCMS) with Variable Energy, Heavy Ion Treatment Technologies, offering Proton-to-Carbon Heavy Ion, for Highly Precise, Conformal and Hypo-Fractionated Radiation Therapy.
  • The advantages of the Best 400 MeV iRCMS are:
    Small beam size small magnets, light gantries smaller footprint
    Flexibility heavy ion beam therapy (protons and/or carbon), beam delivery modalities.
  • University of Wisconsin and Best Medical are excited about the collaboration, as this brings much needed carbon ion therapy to Midwestern states such as Illinois, Wisconsin, Indiana, etc.

ProTom Receives U.S. FDA 510(k) Clearance for Its Radiance 330® Single Room Proton Therapy System

Retrieved on: 
Monday, October 7, 2019
Radiation therapy, Medical physics, Applied sciences, Academic disciplines, Accelerator physics, Proton, Physics, Proton therapy, Radiobiology, Pencil-beam scanning, Pencil, Synchrotron

WAKEFIELD, Mass., Oct. 7, 2019 /PRNewswire/ -- ProTom International Holding Corporation ("ProTom"), a market-leading proton therapy technology manufacturer, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for its Radiance 330 proton therapy system installed at Massachusetts General Hospital ("MGH") in Boston, Massachusetts.

Key Points: 
  • WAKEFIELD, Mass., Oct. 7, 2019 /PRNewswire/ -- ProTom International Holding Corporation ("ProTom"), a market-leading proton therapy technology manufacturer, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for its Radiance 330 proton therapy system installed at Massachusetts General Hospital ("MGH") in Boston, Massachusetts.
  • The Radiance 330 proton therapy system at MGH is a compact, single room system equipped with an advanced pencil beam scanning system and integrated imaging and control system.
  • By using the advanced pencil beam scanning technology, modular designed treatment system and the compact synchrotron particle accelerator, Radiance 330 is a smaller, lighter and cleaner system.
  • "We are delighted to have received the marketing authorization for the Radiance 330 proton therapy system installed at MGH.